Abstract
The 2011 Next-Generation Protein Therapeutics Summit integrated five promising strategic approaches to designing and realizing the next generations of protein and biologic drugs. The conference sessions focused on non-antibody and antibody therapeutics, innovations in improving the physicochemical properties of these drugs, routes of administration, methodologies for reducing unwanted immunogenic reactions, and novel drugs from non-natural amino acids.
Financial & competing interests disclosure
The author works for MannKind Corporation and this article contains a brief discussion of their technologies. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.